Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565061 | 0.90 | ALDH1A1 (0.41) | ALDH1A1KMT2ANCF1L3MBTL3L3MBTL1 | |
| SCHEMBL22565986 | 0.89 | CYP3A4 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL24697464 | 0.87 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL24697413 | 0.87 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL22565072 | 0.86 | CYP3A4 (0.31) | ALDH1A1KMT2A | |
| SCHEMBL24480849 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2AL3MBTL3L3MBTL1 | |
| SCHEMBL24697412 | 0.85 | ALDH1A1 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL22565062 | 0.85 | HRH3 (0.32) | ALDH1A1 | |
| SCHEMBL26743381 | 0.84 | ALDH1A1 (0.36) | ALDH1A1KMT2ANCF1 | |
| SCHEMBL24996228 | 0.84 | ALDH1A1 (0.42) | ALDH1A1NCF1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | ALDH1A1 861/4885KMT2A 2950/4885NCF1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.